Lineage plasticity in cancer: a shared pathway of therapeutic resistance

Á Quintanal-Villalonga, JM Chan, HA Yu… - Nature reviews Clinical …, 2020 - nature.com
Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

Genomic and phenotypic heterogeneity in prostate cancer

MC Haffner, W Zwart, MP Roudier, LD True… - Nature Reviews …, 2021 - nature.com
From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

Androgen receptor activity in T cells limits checkpoint blockade efficacy

X Guan, F Polesso, C Wang, A Sehrawat, RM Hawkins… - Nature, 2022 - nature.com
Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …

Biologically informed deep neural network for prostate cancer discovery

HA Elmarakeby, J Hwang, R Arafeh, J Crowdis, S Gang… - Nature, 2021 - nature.com
The determination of molecular features that mediate clinically aggressive phenotypes in
prostate cancer remains a major biological and clinical challenge,. Recent advances in …

FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer

M Han, F Li, Y Zhang, P Dai, J He, Y Li, Y Zhu, J Zheng… - Cancer Cell, 2022 - cell.com
Prostate cancer adeno-to-neuroendocrine lineage transition has emerged as a mechanism
of targeted therapeutic resistance. Identifying the direct molecular drivers and developing …

Genomic correlates of clinical outcome in advanced prostate cancer

W Abida, J Cyrta, G Heller, D Prandi… - Proceedings of the …, 2019 - National Acad Sciences
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

The DNA methylation landscape of advanced prostate cancer

SG Zhao, WS Chen, H Li, A Foye, M Zhang… - Nature …, 2020 - nature.com
Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

EEW Cohen, RB Bell, CB Bifulco, B Burtness… - … for immunotherapy of …, 2019 - Springer
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer

ML Burr, CE Sparbier, KL Chan, YC Chan… - Cancer cell, 2019 - cell.com
Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy
resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved …

Clinical and biological features of neuroendocrine prostate cancer

Y Yamada, H Beltran - Current oncology reports, 2021 - Springer
Abstract Purpose of Review Neuroendocrine prostate cancer (NEPC) is an aggressive
histologic subtype of prostate cancer that most commonly arises in later stages of prostate …